Phathom Pharmaceuticals Inc. has announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company expects net revenues of approximately $57 million to $58 million, with GAAP operating expenses between $59 million and $61 million and non-GAAP operating expenses of $51 million to $53 million, excluding about $8 million in stock-based compensation. Net cash usage for the quarter is estimated at around $6 million, with cash and cash equivalents totaling approximately $130 million at year-end. For the full year 2025, Phathom anticipates net revenues of $174.5 million to $175.5 million. GAAP operating expenses are expected to range from $315.5 million to $317.5 million, while non-GAAP operating expenses are projected at $284.5 million to $286.5 million, excluding approximately $31 million of stock-based compensation. The company has also reported surpassing one million VOQUEZNA prescriptions dispensed in the United States since launch. Operating profitability is anticipated in the second half of 2026, excluding stock-based compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621738) on January 07, 2026, and is solely responsible for the information contained therein.